Roche's blood cancer antibody outperforms MabThera PMLiVE Roche says it will now press on with phase III testing of GA101 as an alternative to MabThera (rituximab), which was originated by Biogen Idec and is sold by Roche outside the USA and Japan. The first comparative study of GA101 and MabThera (rituximab) ... |
